Pierre Fabre patent expiration
1. Hemangeol patent expiration
HEMANGEOL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8338489 | PIERRE FABRE | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
Oct, 2028
(4 years from now) | |
| US8987262 | PIERRE FABRE | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
Oct, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 14, 2017 |
| Orphan Drug Exclusivity(ODE) | Mar 14, 2021 |
| Orphan Drug Exclusivity(ODE-62) | Mar 14, 2021 |
Drugs and Companies using PROPRANOLOL HYDROCHLORIDE ingredient
Market Authorisation Date: 14 March, 2014
Treatment: Method to treat hemangioma.; Method to treat infantile hemangioma
Dosage: SOLUTION
How can I launch a generic of HEMANGEOL before it's drug patent expiration?
More Information on Dosage
HEMANGEOL family patents
